These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 25128389)
1. Mesenchymal change and drug resistance in neuroblastoma. Naiditch JA; Jie C; Lautz TB; Yu S; Clark S; Voronov D; Chu F; Madonna MB J Surg Res; 2015 Jan; 193(1):279-88. PubMed ID: 25128389 [TBL] [Abstract][Full Text] [Related]
2. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Piskareva O; Harvey H; Nolan J; Conlon R; Alcock L; Buckley P; Dowling P; Henry M; O'Sullivan F; Bray I; Stallings RL Cancer Lett; 2015 Aug; 364(2):142-55. PubMed ID: 25960282 [TBL] [Abstract][Full Text] [Related]
3. Differential drug sensitivity of human neuroblastoma cells. Spengler BA; Ross RA; Biedler JL Cancer Treat Rep; 1986 Aug; 70(8):959-65. PubMed ID: 3731152 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Slovak ML; Hoeltge GA; Dalton WS; Trent JM Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804 [TBL] [Abstract][Full Text] [Related]
6. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines. Ireland CM; Pittman SM; Jones SL; Harnett PR Anticancer Res; 1994; 14(6B):2397-403. PubMed ID: 7872659 [TBL] [Abstract][Full Text] [Related]
7. The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma. Lautz TB; Jie C; Clark S; Naiditch JA; Jafari N; Qiu YY; Zheng X; Chu F; Madonna MB PLoS One; 2012; 7(7):e40816. PubMed ID: 22829886 [TBL] [Abstract][Full Text] [Related]
8. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. Blaheta RA; Daher FH; Michaelis M; Hasenberg C; Weich EM; Jonas D; Kotchetkov R; Doerr HW; Cinatl J BMC Cancer; 2006 Dec; 6():294. PubMed ID: 17181871 [TBL] [Abstract][Full Text] [Related]
9. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Voigt A; Zintl F Med Pediatr Oncol; 2003 Apr; 40(4):205-13. PubMed ID: 12555246 [TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143 [TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide. Yousefi M; Ghaffari SH; Zekri A; Ghanizadeh-Vesali S; Hosseini E; Rostami M; Hassani S; Alimoghaddam K; Ghavamzadeh A Neurochem Int; 2013 Dec; 63(8):809-17. PubMed ID: 24161621 [TBL] [Abstract][Full Text] [Related]
12. Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Zhu H; Zheng J; Xiao X; Zheng S; Dong K; Liu J; Wang Y Oncol Rep; 2010 Jan; 23(1):129-39. PubMed ID: 19956873 [TBL] [Abstract][Full Text] [Related]
13. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Poomthavorn P; Wong SH; Higgins S; Werther GA; Russo VC Endocr Relat Cancer; 2009 Sep; 16(3):991-1004. PubMed ID: 19423615 [TBL] [Abstract][Full Text] [Related]